suramin has been researched along with Carcinoma in 21 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of the current study was to determine the prostate-specific antigen (PSA) and objective response rates and the pharmacokinetics associated with a monthly x 3 one-hour infusion of suramin in 58 patients with hormone-refractory prostate carcinoma." | 9.11 | A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. ( Arrieta, R; Cohn, H; Garcia, J; Giannone, L; Karrison, T; Kugler, J; Ratain, MJ; Stadler, WM; Troeger, T; Vogelzang, NJ; Vokes, EE, 2004) |
| "Using a fixed higher-dose schedule, the efficacy and toxicity of suramin plus hydrocortisone were assessed in patients with metastatic hormone-refractory prostate carcinoma (HRPC)." | 9.09 | Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study. ( Beltrán, C; Berián, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Martínez-Monge, R; Rebollo, J; Rodríguez, J; Sureda, M, 2001) |
| "The antiparasitic drug, suramin, has antiproliferative effects in human carcinoma cells." | 7.68 | Disruption of cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism. ( Cheng, AL; Mitchen, J; Oberley, T; Rago, R; Wilding, G, 1991) |
| "The efficacy of mitotane in providing objective tumour responses in patients with adrenocortical carcinoma (ACC), has been recently questioned." | 6.17 | Cytotoxic chemotherapy for adrenocortical carcinoma. ( Alì, A; Angeli, A; Berruti, A; Dogliotti, L; Paccotti, P; Pia, A, 1995) |
| "Suramin was found to have the potential to induce cell cycle arrest in S-phase CNE-2 cells." | 5.38 | Suramin inhibits the growth of nasopharyngeal carcinoma cells via the downregulation of osteopontin. ( Chen, X; Jiang, S; Li, C; Yang, G; Yue, Y; Zhang, T; Zhang, X, 2012) |
| "Treatment with suramin (Germanin) was begun in August 1987." | 5.28 | [Treatment of metastatic adrenal carcinoma with suramin]. ( Allolio, B; Arlt, W; Jaursch-Hancke, C; Metzler, U; Reincke, M; Winkelmann, W, 1989) |
| "The goal of the current study was to determine the prostate-specific antigen (PSA) and objective response rates and the pharmacokinetics associated with a monthly x 3 one-hour infusion of suramin in 58 patients with hormone-refractory prostate carcinoma." | 5.11 | A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. ( Arrieta, R; Cohn, H; Garcia, J; Giannone, L; Karrison, T; Kugler, J; Ratain, MJ; Stadler, WM; Troeger, T; Vogelzang, NJ; Vokes, EE, 2004) |
| "Using a fixed higher-dose schedule, the efficacy and toxicity of suramin plus hydrocortisone were assessed in patients with metastatic hormone-refractory prostate carcinoma (HRPC)." | 5.09 | Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study. ( Beltrán, C; Berián, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Martínez-Monge, R; Rebollo, J; Rodríguez, J; Sureda, M, 2001) |
| "(1) Suramin is of antineoplastic efficacy in the treatment of metastatic adrenocortical carcinoma." | 3.69 | Suramin in adrenocortical cancer: limited efficacy and serious toxicity. ( Allolio, B; Arlt, W; Reincke, M; Siekmann, L; Winkelmann, W, 1994) |
| "The antiparasitic drug, suramin, has antiproliferative effects in human carcinoma cells." | 3.68 | Disruption of cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism. ( Cheng, AL; Mitchen, J; Oberley, T; Rago, R; Wilding, G, 1991) |
| "Vortex keratopathy occurred in six patients given high-dose intravenous suramin for adrenocortical carcinoma." | 3.67 | Suramin keratopathy. ( Chan, CC; Holland, EJ; Kuwabara, T; LaRocca, R; McAtee, N; Myers, CE; Nussenblatt, RN; Palestine, AG; Stein, CA; Thomas, R, 1988) |
| "Suramin was found to have the potential to induce cell cycle arrest in S-phase CNE-2 cells." | 1.38 | Suramin inhibits the growth of nasopharyngeal carcinoma cells via the downregulation of osteopontin. ( Chen, X; Jiang, S; Li, C; Yang, G; Yue, Y; Zhang, T; Zhang, X, 2012) |
| "His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10." | 1.29 | Acute renal toxicity associated with suramin in the treatment of prostate cancer. ( Bergan, RC; Cooper, MR; Figg, WD; Headlee, D; Humphrey, J; Reed, E; Sartor, O; Thibault, A, 1994) |
| "Treatment with suramin (Germanin) was begun in August 1987." | 1.28 | [Treatment of metastatic adrenal carcinoma with suramin]. ( Allolio, B; Arlt, W; Jaursch-Hancke, C; Metzler, U; Reincke, M; Winkelmann, W, 1989) |
| "The human colon cancer cell line HT-29 produces a growth factor (CRDGF; Mr = 25,000) which inhibits EGF binding to a wide variety of different normal and tumoral cell types in culture." | 1.27 | Autocrine secretion of a colorectum-derived growth factor by HT-29 human colon carcinoma cell line. ( Bettetini, D; Culouscou, JM; Garrouste, F; Marvaldi, J; Pommier, G; Remacle-Bonnet, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (33.33) | 18.7374 |
| 1990's | 10 (47.62) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, S | 1 |
| Chen, X | 1 |
| Li, C | 1 |
| Zhang, X | 1 |
| Zhang, T | 1 |
| Yue, Y | 1 |
| Yang, G | 1 |
| Vogelzang, NJ | 1 |
| Karrison, T | 1 |
| Stadler, WM | 1 |
| Garcia, J | 1 |
| Cohn, H | 1 |
| Kugler, J | 1 |
| Troeger, T | 1 |
| Giannone, L | 1 |
| Arrieta, R | 1 |
| Ratain, MJ | 1 |
| Vokes, EE | 1 |
| Gil, M | 1 |
| Skopińska-Rózewska, E | 1 |
| Radomska, D | 1 |
| Demkow, U | 1 |
| Skurzak, H | 1 |
| Rochowska, M | 1 |
| Beuth, J | 1 |
| Roszkowski, K | 1 |
| Dogliotti, L | 1 |
| Berruti, A | 1 |
| Pia, A | 1 |
| Paccotti, P | 1 |
| Alì, A | 1 |
| Angeli, A | 1 |
| Koga, M | 1 |
| Kasayama, S | 1 |
| Matsumoto, K | 1 |
| Sato, B | 1 |
| Arlt, W | 3 |
| Reincke, M | 3 |
| Siekmann, L | 2 |
| Winkelmann, W | 3 |
| Allolio, B | 3 |
| Figg, WD | 1 |
| Cooper, MR | 1 |
| Thibault, A | 1 |
| Headlee, D | 1 |
| Humphrey, J | 1 |
| Bergan, RC | 1 |
| Reed, E | 1 |
| Sartor, O | 1 |
| Chen, JK | 1 |
| Shen, LS | 1 |
| Chao, HH | 1 |
| Bergström, JD | 1 |
| Westermark, B | 1 |
| Heldin, NE | 1 |
| Calvo, E | 1 |
| Cortés, J | 1 |
| Rodríguez, J | 1 |
| Sureda, M | 1 |
| Beltrán, C | 1 |
| Rebollo, J | 1 |
| Martínez-Monge, R | 1 |
| Berián, JM | 1 |
| de Irala, J | 1 |
| Brugarolas, A | 1 |
| Trieb, K | 1 |
| Dorfinger, K | 1 |
| Neuhold, N | 1 |
| Selzer, E | 1 |
| Wilfing, A | 1 |
| Czernin, S | 1 |
| Hermann, M | 1 |
| Niederle, B | 1 |
| Gessl, A | 1 |
| Vierhapper, H | 2 |
| O'Donnell, BP | 1 |
| Dawson, NA | 1 |
| Weiss, RB | 1 |
| Myers, CE | 3 |
| James, WD | 1 |
| Rago, R | 1 |
| Mitchen, J | 1 |
| Cheng, AL | 1 |
| Oberley, T | 1 |
| Wilding, G | 1 |
| Schwartz, RW | 1 |
| Sloan, DA | 1 |
| Kenady, DE | 1 |
| Mostbeck, G | 1 |
| Waldhäusl, W | 1 |
| Deuss, U | 1 |
| Forgue-Lafitte, ME | 1 |
| Coudray, AM | 1 |
| Bréant, B | 1 |
| Mester, J | 1 |
| Jaursch-Hancke, C | 1 |
| Metzler, U | 1 |
| Stein, CA | 2 |
| LaRocca, RV | 1 |
| Thomas, R | 2 |
| McAtee, N | 2 |
| Culouscou, JM | 1 |
| Garrouste, F | 1 |
| Remacle-Bonnet, M | 1 |
| Bettetini, D | 1 |
| Marvaldi, J | 1 |
| Pommier, G | 1 |
| Holland, EJ | 1 |
| Palestine, AG | 1 |
| LaRocca, R | 1 |
| Chan, CC | 1 |
| Kuwabara, T | 1 |
| Nussenblatt, RN | 1 |
3 reviews available for suramin and Carcinoma
| Article | Year |
|---|---|
Cytotoxic chemotherapy for adrenocortical carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols | 1995 |
Molecular mechanism of androgen-dependent growth in transformed cells. Pathway from basic science to clinical application.
Topics: Amino Acid Sequence; Androgens; Animals; Carcinoma; Cell Division; Fibroblast Growth Factor 8; Fibro | 1995 |
Diagnosis and treatment of primary adrenal tumors.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Aged; Carcinoma; Cushing Syndrome; Diagnosis | 1991 |
3 trials available for suramin and Carcinoma
| Article | Year |
|---|---|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma; D | 2004 |
Cytotoxic chemotherapy for adrenocortical carcinoma.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols | 1995 |
Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progress | 2001 |
16 other studies available for suramin and Carcinoma
| Article | Year |
|---|---|
Suramin inhibits the growth of nasopharyngeal carcinoma cells via the downregulation of osteopontin.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Down-Regulation; Humans; Nasopharynge | 2012 |
Effect of purinergic receptor antagonists suramin and theobromine on tumor-induced angiogenesis in BALB/c mice.
Topics: Animals; Carcinoma; Injections, Subcutaneous; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neopl | 1993 |
Suramin in adrenocortical cancer: limited efficacy and serious toxicity.
Topics: Adrenal Cortex Neoplasms; Adult; Aged; Blood Coagulation; Bone Marrow; Carcinoma; Drug Eruptions; Fe | 1994 |
Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Th | 1994 |
Correlation of transformation from epithelial to mesenchymal-like morphology and endogenous bFGF levels in human nasopharyngeal carcinoma cells.
Topics: Antibodies; Carcinoma; Epidermal Growth Factor; Epithelial Cells; Fibroblast Growth Factor 2; Fibrob | 1994 |
Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells.
Topics: Antineoplastic Agents; Butadienes; Carcinoma; Enzyme Inhibitors; ErbB Receptors; Gene Expression Reg | 2000 |
Suramin affects differentiated and undifferentiated human thyroid epithelial cells in vitro.
Topics: Adenylyl Cyclases; Carcinoma; Carcinoma, Papillary; Cell Adhesion Molecules; Cell Differentiation; C | 1992 |
Suramin-induced skin reactions.
Topics: Carcinoma; Drug Eruptions; Drug Evaluation; Humans; Infusions, Intravenous; Male; Prostatic Neoplasm | 1992 |
Disruption of cellular energy balance by suramin in intact human prostatic carcinoma cells, a likely antiproliferative mechanism.
Topics: Biological Transport; Calcium; Carcinoma; Cell Division; Energy Metabolism; Epidermal Growth Factor; | 1991 |
Effect of suramin in a patient with adrenocortical carcinoma.
Topics: Adrenal Gland Neoplasms; Adult; Carcinoma; Drug Therapy, Combination; Humans; Male; Mitotane; Surami | 1989 |
Suramin for treatment of adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adult; Carcinoma; Female; Humans; Male; Middle Aged; Suramin | 1989 |
Proliferation of the human colon carcinoma cell line HT29: autocrine growth and deregulated expression of the c-myc oncogene.
Topics: Blotting, Northern; Blotting, Southern; Carcinoma; Cell Differentiation; Cell Division; Colonic Neop | 1989 |
[Treatment of metastatic adrenal carcinoma with suramin].
Topics: Adrenal Cortex Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modali | 1989 |
Suramin: an anticancer drug with a unique mechanism of action.
Topics: Adenocarcinoma; Adrenal Cortex Neoplasms; Adult; Antineoplastic Agents; Carcinoma; Female; Humans; K | 1989 |
Autocrine secretion of a colorectum-derived growth factor by HT-29 human colon carcinoma cell line.
Topics: Carcinoma; Colonic Neoplasms; Epidermal Growth Factor; ErbB Receptors; Growth Substances; Humans; Su | 1988 |
Suramin keratopathy.
Topics: Adrenal Cortex; Adrenal Gland Neoplasms; Adult; Carcinoma; Corneal Diseases; Female; Humans; Injecti | 1988 |